PDS Biotech Logo.png
PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
06 sept. 2023 08h00 HE | PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Logo.png
PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting
16 août 2023 08h00 HE | PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of...
PDS Biotech Logo.png
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
14 août 2023 07h30 HE | PDS Biotechnology Corporation
Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the fourth quarter 2023Biomarker data from VERSATILE-002 to be...
PDS Biotech Logo.png
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
14 août 2023 07h00 HE | PDS Biotechnology Corporation
VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer PDS Biotech anticipates initiating the VERSATILE-003 trial in...
PDS Biotech Logo.png
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
07 août 2023 08h00 HE | PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech Logo.png
PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023
02 août 2023 08h00 HE | PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech Logo.png
PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023
25 juil. 2023 08h00 HE | PDS Biotechnology Corporation
Data from ongoing VERSATILE-002 trial to highlight HPV16-specific T cell responses in subjects receiving PDS0101 and KEYTRUDA® for recurrent or metastatic HPV16-positive head and neck cancer FLORHAM...
PDS Biotech Logo.png
PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023
17 juil. 2023 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech Logo.png
PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301
11 juil. 2023 08h00 HE | PDS Biotechnology Corporation
Composition of matter and use patent for Versamune® in combination with PDS0301 allowed in CanadaPDS Biotech’s proprietary combination of Versamune® based PDS0101 and PDS0301 with an immune checkpoint...
PDS Biotech Logo.png
PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 juin 2023 16h05 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 30, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech”), a clinical-stage immunotherapy company developing a growing pipeline of targeted...